Biotech

All Articles

Rivus' period 2 obesity-related heart failure test strikes endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its fat-busting, muscle-sparing medi...

Ovid stops preclinical work, IV system after soticlestat fall short

.Ovid Therapy presently revealed last month that it was actually trimming its own head count as the ...

Eli Lilly opens up $700M nucleic acid R&ampD facility in Boston ma Port

.Eli Lilly has actually opened a $700 thousand R&ampD facility in the Boston ma Port, enhancing its ...

Boundless Bio makes 'small' cutbacks five months after $100M IPO

.Merely five months after safeguarding a $100 thousand IPO, Vast Bio is actually presently laying of...

Halda's $126M will definitely evolve 'hold and get rid of' growth drugs

.The preliminary phases of oncology R&ampD may not be short of appealing brand-new techniques, as we...

Lykos 'disappointments' not disclosing research study offenses with publisher

.Psychopharmacology has pulled 3 short articles concerning midstage medical trial information evalua...

Analysts examine Avidity's DMD gain, revealing subtleties in information

.Avidity Biosciences pleased financiers along with period 1/2 information in Duchenne muscle dystrop...

Actinogen's cortisol blocker fails phase 2 anxiety study

.Actinogen Medical's cortisol blocker has missed out on the primary endpoint of a period 2 research ...

Bivictrix makes a decision going private only means to take ADC right into center

.Antibody-drug conjugates (ADCs) have actually been at the center of several a billion-dollar biobuc...

TPG tops up funds to $580M for assets across lifestyle scientific researches

.Property supervisor TPG, which has actually sustained biotechs including Sionna Therapies as well a...